Profile
| Metric | Value |
|---|---|
| Full Name | Adaptive Biotechnologies Corporation |
| Ticker | NASDAQ: ADPT |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | adaptivebiotech.com |
| Employees | 619 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $18.26 | |
| Price, 1D Change | +15.86% | |
| Market Cap | $3B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.53 | |
| Revenue | $179M | |
| Revenue, 1Y Change | +5.10% | |
| EPS | -$1.08 | |
| EPS, 1Y Change | +30.50% |
Chart
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$1.08 | |
| EPS Estimate | -$0.49 | |
| EPS Est. Change | +55.20% | |
| Revenue | $178.96M | |
| Revenue Estimate | $264.71M | |
| Revenue Est. Change | +47.92% | |
| Current Price | $18.26 | |
| Price Target | - | $20.00 |
| Price Tgt. Change | - | +9.53% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$1.41 | -$1.56 | -10.65% | |
| -$1.11 | -$1.08 | +2.38% | |
| -$0.49 | N/A | +55.20% | |
| -$0.59 | N/A | +45.19% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $172.87M | $170.28M | -1.50% | |
| $177.57M | $178.96M | +0.78% | |
| $264.71M | N/A | +47.92% | |
| $266.08M | N/A | +48.68% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +180.92% | |
| Price, 3Y | +89.03% | |
| Market Cap, 1Y | +190.22% | |
| Market Cap, 3Y | +101.65% | |
| Revenue, 1Y | +5.10% | |
| Revenue, 3Y | +15.95% | |
| EPS, 1Y | +30.50% | |
| EPS, 3Y | +26.58% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $18.26 | |
| SMA 200 | $12.63 | |
| SMA 200 vs Price | -30.84% | |
| SMA 50 | $16.45 | |
| SMA 50 vs Price | -9.92% | |
| Beta | 1.53 | |
| ATR | $1.05 | |
| 14-Day RSI | 62.41 | |
| 10-Day Volatility | 89.89% | |
| 1-Year Volatility | 76.76% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $178.96M | |
| EPS | -$1.08 | |
| Gross Profit | $106.88M | |
| Gross Margin | 59.72% | |
| Operating Profit | -$155.34M | |
| Operating Margin | -86.81% | |
| Net Income | -$159.60M | |
| Net Margin | -89.12% | |
| EBITDA | -$146.31M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.00 | |
| Current Ratio | 2.89 | |
| Quick Ratio | 2.81 | |
| - | ||
| F-Score | 4 | |
| Altman Z-Score | 1.42 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | 11.03 | |
| PB Ratio | 13.64 | |
| EV/EBITDA | -46.46 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $202.71M | |
| Cash & Equivalents | $47.92M | |
| Total Assets | $539.38M | |
| Current Assets | $283.75M | |
| Total Liabilities | $336.89M | |
| Current Liabilities | $98.05M | |
| Total Debt | $222.67M | |
| Short Term Debt | $11.10M | |
| Accounts Payable | $7.27M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $334.30M | |
| Operating Expenses | $262.22M | |
| Cost Of Goods Sold | $72.08M | |
| SG&A | $157.57M | |
| D&A | $19.26M | |
| Interest Expense | $0.00 | |
| Income Tax | $0.00 |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$95.21M | |
| CFI | $77.79M | |
| CFF | $241.00K | |
| Capex | $3.66M | |
| Free Cash Flow | -$98.88M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Morgan Stanley | → | |
| JP Morgan | → | |
| BTIG | → | |
| BTIG | → | |
| Piper Sandler | → | |
| JP Morgan | → | |
| Guggenheim | ||
| TD Cowen | → | |
| Piper Sandler | → | |
| JP Morgan | → |
Analyst sentiment
Institutional ownership
Screeners with ADPT
Data Sources & References
- ADPT Official Website www.adaptivebiotech.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1478320/000119312525267061/0001193125-25-267061-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1478320/000095017025030913/0000950170-25-030913-index.htm
- ADPT Profile on Yahoo Finance finance.yahoo.com/quote/ADPT
- ADPT Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/adpt
FAQ
What is the ticker symbol for Adaptive Biotechnologies Corporation?
The ticker symbol for Adaptive Biotechnologies Corporation is NASDAQ:ADPT
Does Adaptive Biotechnologies Corporation pay dividends?
No, Adaptive Biotechnologies Corporation does not pay dividends
What sector is Adaptive Biotechnologies Corporation in?
Adaptive Biotechnologies Corporation is in the Healthcare sector
What industry is Adaptive Biotechnologies Corporation in?
Adaptive Biotechnologies Corporation is in the Biotechnology industry
What country is Adaptive Biotechnologies Corporation based in?
Adaptive Biotechnologies Corporation is headquartered in United States
When did Adaptive Biotechnologies Corporation go public?
Adaptive Biotechnologies Corporation initial public offering (IPO) was on June 27, 2019
Is Adaptive Biotechnologies Corporation in the S&P 500?
No, Adaptive Biotechnologies Corporation is not included in the S&P 500 index
Is Adaptive Biotechnologies Corporation in the NASDAQ 100?
No, Adaptive Biotechnologies Corporation is not included in the NASDAQ 100 index
Is Adaptive Biotechnologies Corporation in the Dow Jones?
No, Adaptive Biotechnologies Corporation is not included in the Dow Jones index
When was Adaptive Biotechnologies Corporation last earnings report?
Adaptive Biotechnologies Corporation's most recent earnings report was on November 5, 2025
When does Adaptive Biotechnologies Corporation report earnings?
The next expected earnings date for Adaptive Biotechnologies Corporation is February 10, 2026
